The desire to guide product development and remain on the leading edge of cardiac care led Shannon to become a beta testing site for McKesson Cardiology 13.1, which extends remote access with the ability for physicians to view ECG waveforms and results on iPads.
The key take away messages from the 26th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium were bioresorable stents and transcatheter valve technologies will likely become primary interventional tools in the near future.
The Gammex 464 CT phantom better indicates the scanner's performance with a phantom that more accurately mimics a torso. The optional Gammex 464-Ring torso adapter permits the use of the Gammex 464 Accreditation in this type of application
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
The American College of Cardiology announced 35 selected hospitals that are pioneering a team approach to keep patients healthy and at home following admission for heart attack or heart failure. The hospitals from across the country are the first participants in the ACC Patient Navigator Program, which is the first program of its kind in cardiology and supports national efforts to reduce unnecessary patient readmissions.
Metro Health (Michigan) cardiovascular specialist Jihad Mustapha, M.D., is one of the first physicians in the United States to use a new medical device to treat peripheral artery disease (PAD).
Cardiovascular Systems Inc. announced that the first seven patients in Japan have been enrolled in its Coronary Orbital Atherectomy System Trial (COAST) study. Taking place in the United States and Japan, the study is designed to assess the safety and efficacy, as well as economic outcomes, of CSI’s new micro crown Orbital Atherectomy System (OAS) in treating severely calcified coronary lesions in patients suffering from coronary artery disease (CAD). Shigeru Saito, M.D., director of cardiology and catheterization laboratories, Shonan Kamakura General Hospital, Kamakura, Japan, performed the procedures on Oct. 27.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
New physician experience for the Convergent Procedure in the treatment of persistent atrial fibrillation (AF) was presented during a podium talk at the Northeast Cardiothoracic Surgical Society 20th Annual Meeting held last week in East Madison, N.H. William M. Boedefeld II, M.D., of CVT Surgical Center in Baton Rouge, La., reported on 224 patients, 66 percent of whom had persistent or longstanding persistent AF and 34 percent who had paroxysmal AF. At one-year follow-up, 93 percent of patients were in sinus rhythm.
Restenosis, the recurrence of narrowing of the arteries after stenting, is a common risk of this endovascular treatment. There are no well-defined guidelines to treat restenosis, but recent studies have shown excellent results with drug-eluting balloon angioplasty in coronary and femoral artery stents. However, few studies have focused on the carotid arteries, which take blood to the neck and head.
Doctors are more likely to try a new therapy when they are persuaded to do so by an influential colleague, reports a new Northwestern University study whose findings on adopting innovations also have relevance for business, education and research.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
If Marvel’s Captain America can lay still during a magnetic resonance imaging (MRI) exam, so can kids. That’s the message of a special comic book designed to ease children’s fears before they undergo a scan, which requires them to lay still in a narrow, loud machine in order for it to produce clear images. The new Marvel Custom Solutions comic book is included in an “MRI Heroes Kit” developed by Siemens Healthcare and Marvel Custom Solutions in collaboration with Weill Cornell Imaging at NewYork-Presbyterian and Weill Cornell Medical College. The kit is designed to empower young patients by educating them about the procedure in a gentle and compelling way.
Mindray introduced the M9 premium compact ultrasound system at the American College of Emergency Physicians (ACEP) annual meeting , the next generation in point-of-care ultrasound technology. The M9 is designed to provide physicians imaging for immediate clinical management and decision-making.
Abbott has entered into an agreement to purchase Topera Inc., a private, venture-backed medical device company focused on developing electrophysiology technologies to improve the diagnosis and treatment of atrial fibrillation (AF). Through this acquisition, Abbott enters the catheter-based electrophysiology (EP) market, an approximately $3 billion global market that has been growing annually at double-digit rates.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
Sorin Group announced today a $20 million minority investment in Respicardia, a developer of implantable therapies to improve Respiratory Rhythm Management. Under the terms of the transaction, Sorin also acquired the exclusive right to distribute the remed? System for the next five years in selected countries in Europe and an exclusive option to acquire Respicardia in the future. Respicardia is based in Minneapolis.
St. Jude Medical Inc. today announced U.S. Food and Drug Administration (FDA) approval of its TactiCath Quartz irrigated ablation catheter, which gives physicians a real-time, objective measure of the force that the catheter applies to a patient’s heart wall during an ablation procedure. TactiCath Quartz contact-force technology was designed to provide physicians with more control to modify that force during ablation procedures in order to create more effective lesions for patients being treated for paroxysmal atrial fibrillation (AF). The technology is associated with a reduction in the rate of AF recurrence when optimal treatment measures are used.
Miracor Medical Systems announced today the successful launch of its next-generation Pressure-Controlled Intermittent Coronary Sinus Occlusion (PICSO) Impulse System for the treatment of myocardial infarction. The new PICSO Impulse System, consisting of the Impulse Console and Impulse Balloon Catheters, is CE-marked and has already been used to treat patients in the U.K., Ireland and Hungary.